Nutex Health delays Q2 filing, announces $25 million stock buyback

HOUSTON - Nutex Health Inc. (NASDAQ:NUTX), a healthcare company that has seen its stock surge over 230% year-to-date according to InvestingPro data, announced Thursday it will delay filing its second-quarter Form 10-Q due to non-cash accounting adjustments related to stock-based compensation for certain hospitals under construction and in ramp-up phases.

The healthcare company expects to file within the SEC’s five-day grace period and stated that the accounting adjustments will not affect revenue, gross profit, liquidity, working capital, or patient visit numbers.

According to preliminary unaudited results, Nutex reported total revenue of $244 million for the three months ended June 30, 2025, a 220.7% increase from $76.1 million in the same period of 2024. Gross profit rose to $124.9 million, representing 51.2% of total revenue, compared to $22.6 million or 29.7% of revenue in the prior-year quarter. InvestingPro analysis shows the company maintains a "GREAT" financial health score of 3.43 out of 5, with particularly strong profitability metrics.

The company’s Hospital Division recorded 45,573 total visits during the second quarter, up 10.6% from 41,208 visits in the comparable period last year. As of June 30, Nutex held $96.6 million in cash and total assets of $855.1 million. The company’s strong liquidity position is reflected in its healthy current ratio of 2.27, indicating robust ability to meet short-term obligations.

Nutex’s Board of Directors has authorized a stock repurchase program of up to $25 million over the next six months, to begin upon filing of the delayed Form 10-Q. The company stated the repurchase program aims to increase shareholder value and offset dilution from future share issuances related to stock compensation obligations.

The company has canceled its previously scheduled earnings call for August 15 and plans to reschedule it as soon as possible.

Nutex Health operates 24 facilities across 11 states through its Hospital Division, which includes micro-hospitals, specialty hospitals, and hospital outpatient departments, according to the press release statement. Trading at a P/E ratio of 9.23 with a market capitalization of $584 million, InvestingPro analysis suggests the stock is currently slightly undervalued. Discover more insights about NUTX and other healthcare stocks in InvestingPro’s comprehensive research reports, available for over 1,400 US-listed companies.

In other recent news, Nutex Health reported first-quarter earnings that significantly surpassed expectations, with revenue reaching $211.8 million, a 214% increase from the previous year. This surge was primarily due to favorable outcomes in rate arbitrations under the No Surprise Act, contributing around $105 million to the revenue. Benchmark analysts responded by raising the price target for Nutex Health to $300, maintaining a Buy rating, reflecting strong confidence in the company’s financial performance. In another development, Nutex Health shareholders approved the election of seven directors at the recent annual meeting. Meanwhile, the company announced the resignation of Chief Operating Officer Joshua DeTillio, effective August 8, 2025, as he moves to a CEO role elsewhere. Additionally, Nutex Health appointed Grant Thornton as its new auditor following a competitive selection process, replacing CBIZ CPAs P.C. The company has acknowledged material weaknesses in internal controls over financial reporting, which they are addressing. Despite recent stock volatility, Benchmark reiterated its $300 price target for Nutex Health, emphasizing continued support for the company.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.